AI assistant
Capstone Holding Corp. — Director's Dealing 2025
Apr 22, 2025
35323_dirs_2025-04-22_ac1fd79e-946d-4dc1-bb28-582f117a0fd8.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Capstone Holding Corp. (CAPS)
CIK: 0000887151
Period of Report: 2025-02-14
Reporting Person: Lipman Matthew E. (Director, Chief Executive Officer, 10% Owner)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 2650436 | Indirect |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Common Stock Warrants | $75.00 | 2028-10-15 | Common Stock (6322) | Indirect |
Footnotes
F1: Consists of (i) 121,774 shares controlled by Matthew Lipman, through his control of BP Peptides, LLC. Brookstone Acquisition Partners XXI Corporation owns 81% of BP Peptides, LLC. Mr. Lipman owns approximately 4% of Brookstone Acquisition Partners XXI Corporation; and (ii) 2,528,662 shares of Common Stock owned by BPA XIV, LLC, an entity controlled by Matthew Lipman.
F2: Includes a warrant to purchase up to 6,322 shares of Common Stock issued to Brookstone Partners IAC, Inc., the investment manager of BP Peptides, LLC which is controlled by Matthew Lipman and Michael Toporek.